Show simple item record

dc.contributor.authorSemba, Richard D
dc.contributor.authorCotch, Mary Frances
dc.contributor.authorGudnason, Vilmundur
dc.contributor.authorEiríksdottir, Gudny
dc.contributor.authorHarris, Tamara B
dc.contributor.authorSun, Kai
dc.contributor.authorKlein, Ronald
dc.contributor.authorJonasson, Fridbert
dc.contributor.authorFerrucci, Luigi
dc.contributor.authorSchaumberg, Debra A
dc.date.accessioned2014-09-01T15:11:51Z
dc.date.available2014-09-01T15:11:51Z
dc.date.issued2014-04-01
dc.date.submitted2014
dc.identifier.citationJAMA Ophthalmol. 2014, 132 (4):464-70en
dc.identifier.issn2168-6173
dc.identifier.pmid24481410
dc.identifier.doi10.1001/jamaophthalmol.2013.7664
dc.identifier.urihttp://hdl.handle.net/2336/325593
dc.description.abstractIMPORTANCE Advanced glycation end products have been implicated in the pathogenesis of age-related macular degeneration (AMD). OBJECTIVE To investigate the relationship between serum carboxymethyllysine (CML), a major circulating advanced glycation end product, and AMD in older adults. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of a population-based sample of 4907 older adults (aged ≥66 years) in the Age, Gene/Environment Susceptibility-Reykjavik Study in Iceland. EXPOSURES Serum CML and risk factors for AMD. MAIN OUTCOMES AND MEASURES Early or late AMD, assessed through fundus images taken through dilated pupils using a 45° digital camera and grading for drusen size, type, area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System. RESULTS Of the 4907 participants, 1025 (20.9%) had early AMD and 276 (5.6%) had late AMD. Mean (SD) serum CML concentrations among adults with no AMD, early AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (195.5), 634.2 (206.4), and 638.4 (192.0) ng/mL, respectively (to convert to micromoles per liter, multiply by 0.00489; P = .07). Log serum CML (per 1-SD increase) was not associated with any AMD (early and late AMD) (odds ratio = 0.97; 95% CI, 0.90-1.04; P = .44) or with late AMD (odds ratio = 0.94; 95% CI, 0.82-1.08; P = .36) in respective multivariable logistic regression models adjusting for age, sex, body mass index, smoking, and renal function. CONCLUSIONS AND RELEVANCE Higher serum CML concentration had no significant cross-sectional association with prevalent AMD in this large population-based cohort of older adults in Iceland.
dc.description.sponsorshipNational Institutes of Health R01 AG027012 R01 EY017362 Intramural Research Program of the National Eye Institute ZIAEYO0401 Intramural Research Program of the National Institute on Aging NO1-AG-1-2100 Icelandic Heart Association Icelandic Parliament University of Iceland Research Fund Research to Prevent Blindnessen
dc.language.isoenen
dc.publisherAmer Medical Assocen
dc.relation.urlhttp://dx.doi.org/10.1001/jamaophthalmol.2013.7664en
dc.rightsArchived with thanks to JAMA ophthalmologyen
dc.subjectAldraðiren
dc.subjectArfgengien
dc.subjectSjónhimnaen
dc.subjectSjónskerðingen
dc.subjectSjónen
dc.subject.meshAge Factorsen
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshCross-Sectional Studiesen
dc.subject.meshDisease Susceptibilityen
dc.subject.meshEnzyme-Linked Immunosorbent Assayen
dc.subject.meshFemaleen
dc.subject.meshGene-Environment Interactionen
dc.subject.meshGlycosylation End Products, Advanceden
dc.subject.meshHumansen
dc.subject.meshIcelanden
dc.subject.meshLogistic Modelsen
dc.subject.meshLysineen
dc.subject.meshMacular Degenerationen
dc.subject.meshMaleen
dc.subject.meshPrevalenceen
dc.subject.meshRisk Factorsen
dc.subject.meshVisual Acuityen
dc.titleSerum carboxymethyllysine, an advanced glycation end product, and age-related macular degeneration: the Age, Gene/Environment Susceptibility-Reykjavik Study.en
dc.typeArticleen
dc.contributor.departmentWilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2Division of Epidemiology and Clinical Research, National Eye Institute, Bethesda, Maryland. 3Icelandic Heart Association, Reykjavik, Iceland4Department of Medicine, University of Iceland, Reykjavik, Iceland. 4Icelandic Heart Association, Reykjavik, Iceland. 5Laboratory of Epidemiology, Demography, and Biometry, Intramural Research Program, National Institute on Aging, Bethesda, Maryland. 6Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison. 7Department of Medicine, University of Iceland, Reykjavik, Iceland7Department of Ophthalmology, Landspitali University Hospital, Reykjavik, Iceland. 8Longitudinal Studies Section, National Institute on Aging, Baltimore, Maryland. 9Moran Center for Translational Medicine, Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City.en
dc.identifier.journalJAMA ophthalmologyen
dc.rights.accessLandspitali Access - LSH-aðganguren
html.description.abstractIMPORTANCE Advanced glycation end products have been implicated in the pathogenesis of age-related macular degeneration (AMD). OBJECTIVE To investigate the relationship between serum carboxymethyllysine (CML), a major circulating advanced glycation end product, and AMD in older adults. DESIGN, SETTING, AND PARTICIPANTS Cross-sectional study of a population-based sample of 4907 older adults (aged ≥66 years) in the Age, Gene/Environment Susceptibility-Reykjavik Study in Iceland. EXPOSURES Serum CML and risk factors for AMD. MAIN OUTCOMES AND MEASURES Early or late AMD, assessed through fundus images taken through dilated pupils using a 45° digital camera and grading for drusen size, type, area, increased retinal pigment, retinal pigment epithelial depigmentation, neovascular lesions, and geographic atrophy using the modified Wisconsin Age-Related Maculopathy Grading System. RESULTS Of the 4907 participants, 1025 (20.9%) had early AMD and 276 (5.6%) had late AMD. Mean (SD) serum CML concentrations among adults with no AMD, early AMD, and late AMD (exudative AMD and pure geographic atrophy) were 618.8 (195.5), 634.2 (206.4), and 638.4 (192.0) ng/mL, respectively (to convert to micromoles per liter, multiply by 0.00489; P = .07). Log serum CML (per 1-SD increase) was not associated with any AMD (early and late AMD) (odds ratio = 0.97; 95% CI, 0.90-1.04; P = .44) or with late AMD (odds ratio = 0.94; 95% CI, 0.82-1.08; P = .36) in respective multivariable logistic regression models adjusting for age, sex, body mass index, smoking, and renal function. CONCLUSIONS AND RELEVANCE Higher serum CML concentration had no significant cross-sectional association with prevalent AMD in this large population-based cohort of older adults in Iceland.


This item appears in the following Collection(s)

Show simple item record